Oral bioavailability and hypoglycaemic activity of tolbutamide/cyclodextrin inclusion complexes

International Journal of Pharmaceutics

Volumn 202, Issue 1-2, 2000, Pages 165-171

  Veiga, F ^a   Fernandes, C ^a   Teixeira, F ^b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

Bioavailability; Cyclodextrins; Hypoglycaemic activity; Inclusion complexes; Tolbutamide

Indexed keywords

CYCLODEXTRIN; CYCLODEXTRIN DERIVATIVE; TOLBUTAMIDE;

ANIMAL EXPERIMENT; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; HYPOGLYCEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ADMINISTRATION, ORAL; ANIMALS; BETA-CYCLODEXTRINS; CYCLODEXTRINS; EXCIPIENTS; HYPOGLYCEMIC AGENTS; MALE; RABBITS; TOLBUTAMIDE;

EID: 0034691643     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(00)00445-2     Document Type: Article

References (24)

1. Ayres J., Huang H., Albert K. Generic tolbutamide tablet dissolution, intralot and inter-lot variation. J. Pharm. Sci. 73:1984;1629-1633.
2. Babu R., Pankit J. Enhancement of dissolution rate and hypoglycaemic activity of glibenclamide with β-cyclodextrin. Stp Pharma Sci. 5:1995;196-201.
3. Balant L. Clinical pharmacokinetics of sulphonylurea hypoglycaemic activity of glibenclamide drugs. Clin. Pharmacokinet. 6:1981;215-241.
4. Brewster M. Parental safety and applications of 2-hydroxypropyl-β-cyclodextrin. Duchêne D. New Trends in Cyclodextrin and Derivatives. 1991;313-351 Editions de Santé Paris.
5. Brewster M., Anderson W., Menisma D., Moreno D., Webb A., Pablo L., Estes K., Derendorf H., Bodor N., Sawchuk R., Cheung B., Pop E. Intravenous and oral pharmacokinetic evaluation of a 2-hydroxypropyl-β-cyclodextrin-based formulation of carbamazepine in the dog: comparison with commercially available tablets and suspensions. J. Pharm. Sci. 86:1997;335-339.
6. Carminetsky S. Substitution for brand-name drugs. Can. Med. Assoc. J. 88:1963;950-955.
7. Dhanaraju M., Kumaran K., Baskaran T., Moorthy M. Enhancement of bioavailability of griseofulvin by its complexation with β-cyclodextrin. Drug Dev. Ind. Pharm. 24:1998;583-587.
8. Fromming K. Cyclodextrins in drug formulations. Breimer D., Speiser P. Topics in Pharmaceutical Sciences. 1987;169-180 Elsevier, Amsterdam.
9. Kedzierewicz F., Zinutti C., Hoffman M., Maincent P. Bioavailability study of tolbutamide β-cyclodextrin inclusion compounds, solid dispersions and bulk powder. Int. J. Pharm. 94:1993;69-74.
10. Miralles M.J., McGinity J.W., Martin A. Combined water-soluble carriers for coprecipitates of tolbutamide. J. Pharm. Sci. 71:1982;302-304.
11. Mura P., Faucci M.T., Parrina P.L., Furlanetto S., Pinzauti S. Influence of the preparation method on the physicochemical properties of ketoprofen-cyclodextrin binary systems. Int. J. Pharm. 179:1999;117-128.
12. Özdemir N., Ordu S. Improvement of dissolution properties of furosemide by complexation with β-cyclodextrin. Drug Dev. Ind. Pharm. 24:1998;19-25.
13. Pitha J., Pitha J. Amorphous water-soluble derivatives of cyclodextrins: nontoxic dissolution enhancing excipients. J. Pharm. Sci. 74:1985;987-990.
14. Soliman O.A.E., Kimura K., Hirayama F., Uekama K., El-Sabbagh H.M., El-Gawad A., Hashim F.M. Amorphous spironolactone-hydroxypropylated cyclodextrin complexes with superior dissolution and oral bioavailability. Int. J. Pharm. 149:1997;73-83.
15. Szejtli J. Cyclodextrins, properties and applications. Drug Invest. 2(4):1990;11-21.
16. Tillement J. The binding of drug to blood plasma macromolecules: recent advances and therapeutic significance. Adv. Drug Res. 13:1983;75-76.
17. Torres-Labandeira J., Blanco-Mendez J., Vila-Jato J. Biopharmaceutical stability of the glibonuride/β-cyclodextrin inclusion complex after one year of storage. Stp Pharma Sci. 4:1994;235-239.
18. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen acceptor. Ann. Clin. Biochem. 6:1969;24-28.
19. Uekama K., Otagiri M. Cyclodextrins in drug carrier systems. CRC Crit. Rev. Ther. Drug Carrier Syst. 3:1987;1-40.
20. Varley A. The generic inequivalence of drugs. JAMA. 206:1968;1745-1754.
21. Veiga F., Teixeira-Dias J., Kedzierewicz F., Sousa A., Maincent P. Inclusion complexation of tolbutamide with β-cyclodextrin and hydroxypropyl-β-cyclodextrin. Int. J. Pharm. 129:1996;63-71.
22. Ventura C.A., Tirendi S., Puglisi G., Bousquet E., Panza L. Improvement of water solubility and dissolution rate of ursodeoxycholic acid and chenodeoxycholic by complexation with natural and modified β-cyclodextrins. Int. J. Pharm. 149:1997;1-13.
23. Vila-Jato J., Blanco J., Torres J. Biopharmaceutical aspects of the glibornuride-β-cyclodextrin inclusion compound. Stp Pharma Sci. 3:1987;28-32.
24. Vila-Jato J.L., Blanco J., Torres J.J. Biopharmaceutical aspects of the tolbutamide-β-cyclodextrin inclusion compound. Il Farmaco. 43:1988;37-45.